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Abstract
Wilson's disease is a rare autosomal recessive disorder of copper metabolism that often proves a
difficult diagnosis for the both the clinician and pathologist largely because of its low incidence and
variable presentations. There have been few studies detailing the histopathological features of hepatic
specimens in patients with Wilson's disease and fewer correlating these features with clinical
presentation. When left untreated, the disease is ultimately fatal, thus good diagnostic criteria that take
into account the histopathological features of the disease is important. The aim of this study was to
evaluate the histopathological features of hepatectomy and biopsy specimens in patients with Wilson's
disease and correlate these features with the clinical parameters of these patients. Twelve biopsy and
hepatectomy specimens from patients with Wilson's disease were reviewed and placed into three
categories: (A) Near normal/mild, (B) Chronic hepatitis and (C) Acute injury on chronic
hepatitis/decompensated cirrhosis. The clinical presentations were reviewed and any correlation
between clinical parameters and anatomic features reported. Histopathological features consistent with
previous findings in the early stages of Wilson's disease were found in group A with clinical findings in
this category of mild elevation of transaminases. In group B, while typical markers of chronic hepatitis
were found, glycogenated nuclei, a feature often reported as prominent in specimens with Wilson’s
disease hepatitis was absent. There was one patient with relevant laboratory data in this group, which
was notable for mild elevations of transaminases. In group C, features of acute on chronic injury were
found. Regarding clinical parameters, transaminases and bilirubin levels were increased, and alkaline
phosphatase:total bilirubin ratio was consistent with previously reported findings of fulminant hepatic
failure in Wilson’s disease. Urinary copper levels increased with increasing levels of histopathological
injury. Staining for copper proved to be an unreliable method of diagnosis. This characterization of
the histopathological and clinical features of Wilson’s disease further elucidates the challenge of
Wilson’s disease but also serves to provide some guidance to both clinician and pathologist as to how
recognizing the variable presentations of the disease may help in establishing a diagnosis.
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Introduction

Wilson's disease is an autosomal recessive disorder of copper metabolism named for Samuel
Kinnier Wilson. He initially described it as progressive lenticular degeneration because of case
observations of patients with lenticular nucleus degeneration and cirrhosis of the liver1. The disease
has a prevalence of 1 in 30,000 worldwide. In some areas, prevalences as high as 1 in 2,600 have been
reported. These areas are typically those of high consanguinity2.

The etiology of Wilson’s disease involves greater than 300 mutations3 in the gene encoding a P
type ATPase ATPB7, which is involved in both the incorporation of copper into apoceruloplasmin, a
copper carrying protein in the hepatocyte, and into bile for excretion. Malfunction or absence of
ATP7B leads to a build up of free (unbound) copper in the brain, cornea and liver. The clinical
consequences of this build up are neuropsychiatric (Parkinsonian symptoms, depression, suicidality),
ophthalmologic (Kaiser-Fleischer rings i.e. copper build up in the irises of affected individuals) and
hepatic (steatosis, cirrhosis, hepatitis).

With early diagnosis and implementation of treatment (primarily chelation therapy), symptom
progression and, in some cases, symptom onset can be thwarted. Even though there are regularly
updated diagnostic criteria4, Wilson's disease is known for its high phenotypic and genotypic
heterogeneity, which makes it a diagnostic challenge for clinician and pathologist alike. In addition,
though early treatises have described the pathology of Wilson disease in detail5, more recent discourses
have not been as comprehensive, nor has there been significant correlation between clinical and
pathologic features. The aim of this project was to describe the spectrum of pathological changes of
Wilson's disease in our patients with emphasis on correlation with clinical features and diagnostic
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parameters.

Wilson's disease mutations and Molecular Pathology

The genetics, molecular pathology and pathophysiology of the disease have been described
extensively6. In summary, mutations of the Wilson disease gene result in abnormal metabolism of
copper. Dietary copper is primarily metabolized by the liver and circulates through the body as
ceruloplasmin with help from P type ATPases ATP7A and ATP7B. While both ATP7A and ATP7B
are copper transporting proteins, they serve different physiological functions due to the difference of
their expression in tissues. ATP7A is primarily localized in the basement membrane of the enterocyte
and serves to transport copper into portal circulation. ATP7B, however, is present in the hepatocyte
and plays a major role in the incorporation of copper into apoceruloplasmin. Because of their varying
roles, mutations in ATP7A and ATP7B inevitably cause different diseases. Mutations in the ATPase
ATP7A have been implicated in Menke’s disease, an X-linked neurodegenerative disease in which
hypocupremia is the main laboratory diagnostic feature. Mutations in ATP7B (located on chromosome
13) are responsible for the development of Wilson’s disease.

ATP7B is primarily localized to the trans-Golgi network of the hepatocyte. Copper enters the
hepatocyte via a copper transporter Ctr1. The copper chaperone ATOX1 then delivers intracellular
copper to ATP7B. There, ATP7B facilitates the binding of copper to apoceruloplasmin and the
subsequent secretion of holoceruloplasmin (copper bound to apoceruloplasmin) into plasma. Biliary
excretion of copper also involves ATP7B however, there is direct interaction with another protein,
COMMD16 (previously known as MURR1). The exact function of this ubiquitous protein is yet to be
elucidated. However, it is absent in dogs with a non-Wilsonian form of copper toxicosis, Further
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investigation showed that COMMD1 is able to bind to ATP7B and aid in the transport of ATP7B
bound copper from the trans-Golgi to the bile canaliculus7.
Ceruloplasmin acts as an oxidase in selected substrate reactions1. Interestingly, ceruloplasmin
is the major ferroxidase in the body and also aids in iron efflux. The associated disorder of iron
metabolism leads to increased liver iron stores so much so that some Wilson's disease patients with
hypoceruloplasminemia have been mistakenly diagnosed with hereditary hemochromatosis because of
apparent iron overload in the liver1.

ATP7B is a large 21 exon gene which codes for a 1465 amino acid transmembrane protein. The
carrier frequency of the gene for this protein is 1 in 90 while the gene frequency is 0.56%8. The most
common mutation detailed in Wilson's disease is H1069Q, it is found in 37% to 63% of patients with
Wilson’s disease of European ancestry3. This mutation leads to a failure of trafficking of the protein to
its usual position in the trans-Golgi. Other, more recently discovered mutations include R778L (the
protein is mislocalized to the endoplasmic reticulum) and P992L found with high frequency in patients
with Wilson’s disease of Chinese ancestry presenting with primarily hepatic complaints3.

Most

recently, methylenetetrahydrofolate reductase (MTHFR) mutations found in Wilson’s disease patients
were implicated as a potential cause for the high phenotypic variability of the disease. Patients with
particular polymorphisms were less likely than others to exhibit the neurological Wilson’s disease
phenotype9.

There have been some studies attempting to detail the genotype-clinical phenotype correlation
in Wilson's disease10,11. This proves difficult as there are numerous mutations of ATP7B and each
mutation is assumed to have significant pleiotropy. In fact, there may be associated mutations in nonATP7B proteins such as COMMD1, which may cause similar symptoms. Mutations also vary

4
extensively by population. In screening recommendations for example, in Northern Chinese
populations exons 8, 12, 13, 16 and 18 should be screened while exons 5,8, 12, 13 and 16 should be
screened in Hong Kong9. All of these factors thus limit the clinical application of molecular studies as
a primary tool of diagnosis. Identification of unique pathological features in liver biopsies therefore
potentially presents a reliable ancillary method of making the diagnosis when fulfillment of diagnostic
criteria is unattainable.

Electron Microscopy

Light microscopy of liver biopsies in patients with Wilson's disease has yielded a variety of
findings and presents a challenge for the pathologist. In general, features described have included
steatosis, glycogenated nuclei and occasional positive staining with rhodanine stains. Published studies
on the ultrastructural pathology of Wilson's disease have been limited, partly due to the absence of an
electron microscope in most institutions as a standard tool for evaluating pathology specimens, and
partly due to the onset of molecular techniques and the readiness with which copper can be quantified
in the liver. Other diagnostic tools explored include diagnosis of Wilson's disease by skin biopsy12. In
a patient presenting with Kayser Fleischer rings and xerosis of the skin, light microscopy of the skin
showed hyperkeratosis. Electron microscopy showed dilatation of intercellular space and lysosomes
with a heterogenous and granular appearance (incidentally all nonspecific findings of xerosis).
However, spectophotometric measurement determined that copper levels in the skin were significantly
higher than the control, one of few studies to highlight skin as another potential organ damaged by
excess copper.

Transmission electron microscopy along with energy dispersive x-ray spectroscopy have shown
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lipofuscin particles containing copper-sulfur (cuprothioneins) and iron phosphorous complexes in the
hepatocyte lysosomes of one patient with Wilson's disease13. This is considered to be a diagnostic
ultrastructural feature. Although other diagnostic features include mitochondrial enlargement and
widening of intercristal spaces suggested to be pathognomonic of Wilson’s disease, they are unreliable
in the setting of cholestasis13.

Light Microscopy

In early stages of the disease, the damage incurred by copper accumulation has been associated
with macrosteatosis, microsteatosis and glycogenated nuclei14. Mallory bodies can be seen in up to
50% of biopsy specimens. There are few reports on Wilson’s disease patients presenting with acute
hepatitis; their biopsies typically show ballooning of hepatocytes, apoptotic bodies, cholestasis and
sparse lymphocytic infiltrate14. In Acute Liver Failure (ALF) histopathology resembling fulminant
hepatitis is typically observed. This is characterized by microvesicular steatosis, marked balloon
degeneration, apoptosis, pigment laden Kupffer cells and parenchymal dropout with lobular collapse.

As the disease progresses to cirrhosis, portal inflammation, focal necrosis and glycogenated
nuclei are common findings in hepatic specimens. The literature points to steatosis, glycogenated
nuclei and the presence of Mallory bodies in periportal liver cells as features used to distinguish the
chronic hepatitis of Wilson’s disease from other more common etiologies14. Autoimmune hepatitis is
often mentioned as appearing similar to Wilson’s disease. And while lobular necroinflmmatory
lesions, ballooning degeneration and interface hepatitis are diagnostic features of both, giant cell
change is predominant in the former.
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In some cases, cirrhosis develops. A mixed micro/macronodular pattern may be observed
although most reports show a macronodular pattern of cirrhosis. Features observed in the chronic
hepatitis of Wilson’s disease are also observed (i.e. inflammation, Mallory bodies within hepatocytes)
after well developed cirrhosis.

Staining

Standard staining is neither sensitive nor specific for the detection of tissue copper. Initially
hematoxylin was used for the demonstration of tissue copper. Further investigation into the diagnosis
of Wilson's disease via histochemical visualization of tissue copper led to the development of the now
commonly used rhodanine and rubeanic acid stains. Other less common stains are: diphenylcarbazide,
Waterhouse method, cresyl violet stain, dithizone and Timm's method. The orcein method is the most
recent development for detecting tissue copper, it was developed in 1974 and stains metallothioneins
(copper-binding proteins).

Consensus on the distribution and staining of copper within the liver in patients with Wilson’s
disease has not been achieved and remains controversial since there are varying reports in the literature.
It has been shown that in the early stages of the disease, copper is distributed throughout the hepatocyte
cytoplasm14. As the disease progresses, in addition to cytoplasmic distribution, copper is also seen in
the lysosomes of hepatocytes and then finally solely in lysosomes in patients with advanced disease.
Copper is reportedly rarely seen in the cirrhotic stage of Wilson’s disease14.

Injury progression
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In the literature, the typical patient with Wilson's disease will develop cirrhosis in the second
decade of life due to copper's damaging effect on liver parenchyma. However, histopathological
features consistent with cirrhosis have been found in patients as young as 5 years of age and other
changes such as fibrosis and inflammation were found in Wilson’s disease patients as young as 4
months and 23 months respectively10. Due to these findings and others, there is not any proven
relationship between age at diagnosis and progression to cirrhosis. There are however some
individuals with primarily neurological manifestations of Wilson’s disease who may not progress to
cirrhosis. Their liver histology will however may still show some abnormality.

There have been no standardized categories for the hepatic pathological injury progression in
Wilson’s disease because of its heterogeneity of presentation. Previous reports have categorized the
clinical and pathological features in patients with Wilson's disease into: fatty liver, acute hepatitis,
resembling autoimmune hepatitis, cirrhosis: compensated or decompensated and acute liver failure4.
These categories however are not rigid and overlap is inevitable

Clinical Presentation and Parameters

As previously mentioned before, the challenge of Wilson's disease lies in its heterogeneous
clinical presentation. It can present predominantly with derangement of liver function, particularly in
children. Patients may present as completely asymptomatic and have incidental findings of elevated
transaminases, or can present with symptoms resembling acute viral hepatitis, fulminant liver failure
and decompensated cirrhosis. Jaundice and hemolytic anemia are also relatively common occurrences
in patients with Wilson’s disease. Clinical findings – which contribute to the ambiguity of its diagnosis
- include elevated gamma-globulin levels and positive ANA and anti-SMA14.
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In the second or third decades of life, neuropsychiatric disease is a more common initial
presentation than clinical hepatic disease. 75% of cases present with neurological manifestations and
25% present with both hepatic and neurological presentations after the age of 2010. These
neuropsychiatric changes include behavioral abnormalities, psychosis and Parkinsonian features
(micrographia, tremor, dysarthria and spasticity among others). Less frequently, extrahepatic nonspecific features that include renal dysfunction (aminoaciduria), EKG abnormalities and osteoarthritis
may be the initial presentation. While neuropsychiatric features are common initial findings, as the
disease progresses, the most common finding is predominantly hepatic, varying from fatty change, to
hepatitis to cirrhosis2. Hepatocellular carcinoma is fairly uncommon in Wilson’s Disease although few
cases have been reported14.

The disease is typically diagnosed in patients between the ages of 5 and 40 years old, however
molecular studies have found ATPB7 mutations in 70 year old patients6. Diagnosis of Wilson's disease
has proven difficult despite published diagnostic criteria. The diagnosis typically involves the presence
of Kaiser Fleischer (KF) rings, a ceruloplasmin less than 20mg/dl and measurement of liver copper
levels. Liver copper levels > 250 micrograms/g dry weight (normal range <35 micrograms/g dry
weight) and urinary copper content (24 hr urinary copper levels > 40mcg /24h4) support the diagnosis
of Wilson’s disease . While dry liver copper levels are the gold standard, acquiring a tissue sample
from a patient with liver disease carries with it significant risk (bleeding due to coagulopathy, infection
etc), thus other more routine chemistries are used in initial investigation. Twenty-four hour urinary
copper has also proven beneficial in the diagnosis of Wilson’s, however; collection is difficult,
particularly in newborns. In addition, in patients who were not suitably educated prior to testing, tap
water washing of the urine bottle may contaminate the sample9.
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While the criteria mentioned here have been considered sufficient for the diagnosis of Wilson’s
disease, there have been numerous reports of patients with overlooked Wilson’s disease when they
were used, particularly in children. In a recent study of 57 children with a previously received
diagnosis of Wilson’s disease, KF rings were found in 50% of patients older than 8 years old and in
only 7% of patients younger than 8 years of age10. Diagnosis in these vague cases was complemented
with urinary copper excretion before and after penicillamine (a copper chelator) challenge, copper
excretion increased sixteen fold after penicillamine challenge. Liver copper content (the current gold
standard) was also used to establish the diagnosis in the absence of more common criteria.

Aminotransferase levels are typically abnormal but have not yet been found to correlate with
severity of the disease. In some studies,the combination of an AST to ALT ratio greater than 2.2 and a
Alkaline phosphatase to Bilirubin ratio greater than 4 has been shown to be consistent with Wilson's
disease in patients presenting with acute liver failure with a sensitivity that approaches 100%4.

With the discovery of more ATP7B mutations in Wilson’s disease, and the rapid advancement
of genetic testing, it is plausible to assume that molecular testing may play a larger role in challenging
cases of Wilson’s disease. However, due to the rare nature of the disease, routine molecular testing may
prove low yield and not cost effective. Nevertheless, it is recommended that such studies only be used
in cases in which the diagnosis is difficult even with both clinical and biochemical testing4. It must be
noted though that most patients with Wilson’s disease are compound heterozygotes, thus genetic
testing may only prove beneficial in populations with a high incidence of certain mutations such as
those populations in the Canary Islands or other such areas with high consanguinity.

10
Correlations

There are few studies detailing the correlation of histopathological features of Wilson's disease
with symptomatology or outcome10,15. In one study in children with Wilson's disease, symptomatic
patients were more likely to have cirrhosis while asymptomatic patients were more likely to have
histological findings consistent with steatosis. Also, in the same study, there were no significant
correlations between clinical outcome and histopathological features. In another study in which serial
liver biopsies of twelve patients with Wilson's disease were reviewed, it was found that hepatic copper
concentration and aminotransferase levels do not correlate with progression of hepatic
histopathology15.

Treatment

Treatment of the disease is most beneficial when diagnosed early in life. Medical therapy is
targeted toward reducing the amount of copper accumulations. This can be done with copper chelation
(trientine, penicillamine) or zinc, which acts by both reducing the intestinal absorption of copper and
inducing the formation of the endogenous copper chelator metalothein. In some cases the copper
chelator is combined with zinc as a combined therapy presumably to utilize to methods of increased
copper excretion and decreased copper absorption16.

In a 2010 retrospective study of 288 Wilson’s disease patients in Germany, discontinuation of
zinc monotherapy and combination therapy occurred with greater frequency than in the cohort on
chelator therapy alone. The authors of this study blamed this apparent discontinuation of the high rate
of adverse events in the zinc cohort. These events included death and liver transplantation and

11
concluded that chelating agents proved more successful at preventing hepatic deterioration than zinc. It
was recommended that zinc therapy be an alternative for asymptomatic or in patients with solely
neurological manifestations of Wilson’s disease16.

Side effects of standard therapy with penicillamine include bone marrow toxicity, elastosis
cutis, nephrotoxicity and lupus like syndrome. These severe side effects often lead to noncompliance
in roughly a third of patients16.

Antioxidants such as Vitamin E are sometimes used as adjunctive therapy; its efficacy in
decreasing clinical symptoms however is unknown due to a lack of studies. Patients are also advised
on low copper diets and avoidance of well water. In the event of acute liver failure however, liver
transplantation is both life saving and curative.
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Statement of purpose, specific hypothesis and specific aims

Given that the presentation of Wilson’s disease was so variable, it was hypothesized that there
was a relationship between the pathologic features, the clinical presentation and markers of liver injury
(Liver Copper content, 24hr urinary copper, Transaminases, Bilirubin). The objective of this study was
to fully characterize the varying pathologic changes in the livers of patients with Wilson's disease and
correlate these findings with symptomatology, detailed clinical parameters and clinical outcome.
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Materials and Methods

Pathology specimens from 14 patients with an established diagnosis of Wilson disease were
retrieved from the hospital database. Patients were selected based on their fulfillment of either clinical,
laboratory or genetic criteria for Wilson disease as well as the availability of surgical pathology
material for review. The demographics, clinical presentation, laboratory data, including alanine
aminotransferase (ALT), aspartate aminotranserase (AST), alkaline phosphatase (ALK), prothrombin
time (PT)/international normalized ratio (INR), total and direct bilirubin (TB/DB), alphafetoprotein
(AFP), urine copper (Cu) and ceruloplasmin (CP), imaging, studies and clinical progression were
reviewed. Routine H&E, Trichrome, Rhodanine copper and Perl iron stains performed on liver
biopsies and/or resections were reviewed and the histological features documented. Pathologic changes
were staged using the Batts and Ludwig criteria17 (0:No fibrosis, 1: Fibrous portal expansion, 2:
Periportal or Rare portal- portal septa, 3: Fibrous septa with architectural distortion; no obvious
cirrhosis 4: Cirrhosis). Steatosis was characterized as mild (0-30%), moderate (>30% - 60%) and
severe (>60%). Iron was graded from 1-4 based on intensity and distribution.
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Results

Pt #

1

Clinical History

Lab
Studies
AST/ALT

CPL

54 y/o male presented
with Parkinsonian
symptoms with
significant anxiety and
intermittent depression
51 y/o male

18, 19:
0.95

3
2

14 y/o female
37 y/o male
evaluated
presented
with
acute
for elevated
fulminant
hepatic
transaminases
failure

133, 34:
70/150
3.9

7

10

7 y/o male evaluated
for elevated liver
enzymes (incidental
finding
afterpresented
23
y/o male
presenting
with
with
subfulminant
Kawasaki’s
disease)
hepatic
failure
18 y/o male evaluated
for persistently
elevated transaminases
and low ceruloplasmin

118, 87:
1.36

3

27, 44:
0.616

7

12

4
11

7
5

35 y/o female with
long
standing
28
y/o
male diagnosed
Wilson’s
by
biopsydisease
after sister
was diagnosed with
Wilson’s

6

19 y/o female
presented with
decompensation of
50y/o female with
cirrhosis
Wilson’s disease
presented with
decompensated
cirrhosis

8

5

Urine Cu
(mcg/24h)
65

Liver Cu
(mcg/g)
620

Specimen

Histology

Needle
biopsy

No significant fibrosis (Stage 0), minimal
portal inflammation, no interface hepatitis,
patchy balloon degeneration and some
glycogenated nuclei. No significant
steatosis. Copper and Iron negative
Portal, periportal and focal bridging
fibrosis, stage 3. mild to moderate
lymohocytic and neutrophilic portal
inflammation with mild interface activity.
Mild microvesicular steatosis with
occasional ballooning degeneration and
Mallory. No glycogenated nuclei. Iron
negative, copper not done.
Cirrhosis. Moderate portal
Mild portal fibrosis, inflammation
stage 1. Minimal
lymphoplasmacytic
with
portal inflammation,
no interface
hepatitis;
moderate
to marked interface
ductular
Mild macrovesicular
and moderate
activity;
Moderate steatosis,
Mallory
microvesicular
steatosis.
Someand
hyaline,
scattered
neutrophilic
glycogenatedlobular
nuclei, inflammation
patchy groundwith
glasslymphocytic
like hepatocytes.
Copper and
Iron
hydropically
degenerated
hepatocytes
with
negative.
hepatocellular
cholestasis and bile plugs.
Occasional acidophilic bodies. Focal
Mild portal
fibrosis,stage
1 minimal
portal
copper
positivity
in periseptal
hepatocytes.
inflammation.
Moderate
macrovesicular
Iron
(1+) positive
in occasional
hepatocyte
microvesicular
and in
macrophagessteatosis with focal
hepatocellular
ballooning.
Scattered
Bridging
fibrosis,
stage 3, marked
glycogenated
nuclei.Marked
No copper
or iron
pericellular
fibrosis.
portal
lymphoplasmacytic, eosininophillic and
Mild portal fibrosis,
stage 1with
minimal
portal
neutrophillic
inflammation
marked
inflammation,
no significant
interface
interface
inflammatory
and ductular
hepatitis.Lobular
Abundant
glycogenated
nuclei,
activity.
disarray
with extensive
patchy ballooning/degeneration,
no
ballooning
degeneration, abundant
significant steatosis,
no Mallory.
Negative
glycogenated
nuclei and
rare Mallory
iron and Hypereosinophilc
copper.
hyaline.
hepatocytes.
Iron
andperiportal
copper negative
Portal,
and pericentral fibrosis
with focal with
bridging
without
cirrhosis
Cirrhosis,
abundant
pericellular
(Stage 3).Extensive
Also prominent
sinusoidal
fibrosis.
parenchymal
loss, with
fibrosis. Mild
to moderate
lymphocytic
interface
ductular
activity and
marked
inflammation, mild
interface hepatitis
and
hepatocellular
and cannalicular
cholestasis.
mild bile ductular
proliferation.
Lobular
Extensive
ballooning
degeneration
with
disarray, with
moderate micro and
moderate
lymphoplasmacytic
macrovesicularand
steatosis
(Grade 2-3 on a
inflammation
some glycogenated
scale ofHypereosinophillic
0 to 4), patchy hepatocellular
nuclei.
hepatocytes.
swelling
and occasional
acidophil(2+)
bodies.
Rare
copper,
Iron in hepatocytes
No Mallory
hyaline.
Copperdropout,
and Iron
Cirrhosis
with
parenchymal
negative.septal lymphoplasmacytic and
marked
some eosinophilic inflammation with
Cirrhosis.proliferation.
Mild to moderate
ductular
Mild interface
lymphoplasmacytic
septal
inflammation,
hepatitis.
No significant
nodular
mild ductular proliferation. No significant
interface hepatitis. Granular eosinophilc
cytoplasm with minimal steatosis (<1%).
Rare Mallory, no glycogenated nuclei.
Copper in rare periportal hepatocytes. Iron

Biopsy

77, 239:
0.32

131, 101:
1.3

16

47, 36: 1.3

3

45, 37: 1.2

4

143

650

Transplant
Needle
hepatectomy
Biopsy

Biopsy
12,265

1235

Biopsy

184

353

Biopsy

1559

600
69

Biopsy
Hepatectom
y

Explant
54

690

Transplant
Hepatectom
y

15
6

19 y/o female
presented with
decompensation of
cirrhosis

47, 36: 1.3

3

9

17y/o female
presented with scleral
icterus, lethargy and
abnormal liver
enzymes

173, 8:
21.6

22

13

64y/o female with
long standing
Wilson’s disease,
presented with acute
liver failure

198, 50:
3.96

17

14

13y/o male

(035)

(035)

18

19

70

Explant

ALK
(30130)

(<14)

(0.91.4)

0.9

59

10.9

150

0.46

NA

118

87

1.3

77

239

45

3
4

Biopsy
Plts

Hbg

1

440

14.3

NA

NA

NA

NA

279

10.1

1

408

12.1

0.3

122

10.5

0.9

168

15.7

37

1.2

135

14.9

1.5

71

133

34

3.9

15

17.9

2.2

27

44

0.6

163

13.6

131

101

1.3

147

47

36

1.3

9

173

8

13

198
AVG
Sd

1
2
10

NN/M

11
8

5
6

CH/C

AOCI

AST/ALT

Cirrhosis with parenchymal dropout,
marked septal lymphoplasmacytic and
some eosinophilic inflammation with
ductular proliferation. Mild interface
hepatitis. No significant nodular
inflammation; giant cell change with
periportal ballooning degeneration,
cholestasis, early Mallory and occasional
foam cell appearance. Iron in hepatocytes
(3+)
Cirrhosis, mild chronic septal
inflammation with moderate bile ductular
proliferation. Mild to moderate
macrovesicular steatosis, extensive
ballooning degeneration with focally
prominent Mallory hyaline. Marked
Hepatocellular and canalicular cholestasis
with focally marked copper accumulation,
mild hepatocellular iron.

Explant

INR

Group

ALT

>5000

PT

#

AST

Explant

Cirrhosis. Abundant pericellular fibrosis.
Mild lymphoplasmacytic septal
inflammation, and ductular proliferation,
conspicuous acidophil bodies, marked
cholestasis. Extensive ballooning
degeneration, cholestasis and occasional
periportal Mallory bodies. Copper stains
are positive in occasional hepatocytes.
Rare iron.
Cirrhosis. Abundant pericellular fibrosis.
TB
DB septal
Mild lymphoplasmacytic
Alb
ALK/TB
inflammation, and ductular proliferation,
conspicuous
(<1.2)acidophil
(<0.2)
bodies, marked
cholestasis. Extensive ballooning
4.3degeneration,
0.34 cholestasis
0.1 and occasional
173.5
Copper
NAperiportal
NAMallory bodies.
NA
NAstains
are positive in occasional hepatocytes.
4.2
0.23
0.06
1213.0
Rare iron.
4.7

1.71

0.32

71.3

13.3

3

1.38

0.34

97.8

197

4.5

3.4

10.5

6.56

1.4

1.2

75

14

4.7

0.93

0.18

175.3

22

2.2

159

6.2

2.4

8.64

5.45

17.0

99

21.9

3.6

67

10.1

3

8.16

3.98

12.1

21.6

2

29.6

2.9

146

9.5

2.3

47.8

39.5

0.0

50

3.9

162

35.6

8.8

158

11.4

2

22.7

17

7.1

94.2

73.2

3.6

118

18.7

2.5

189

11.1

3.4

10.2

7.4

11.6

60.2

67

68.7

80.9

8.6

2.4

132

3.6

1

15

12.5

5.4

Table 1. Available demographic data and histopathology for all patients with Wilson’s disease.
Table 2. Available clinical/laboratory data. NN/M (Near normal/Mild), CH/C (Chronic Hepatitis/Cirrhosis), AOCI (Acute
on Chronic Injury)

16
Demographics, specimens, histopathology, clinical and laboratory data are presented in Tables
1 and 2. Cases highlighted in green correspond to the near normal/mild category; cases in blue
correspond to the chronic hepatitis category while cases in red correspond to the acute on chronic
injury category.

Demographics

Of the cases reviewed, there were 8 males and 6 females of age ranges 7 – 64 years at time of
biopsy/resection, with a mean age of 31 +.18 years. 2 Patients were Caucasian, 2 were Asian, 1 was
Black, 2 were Hispanic, 2 unknown and 4 of the patients listed their races as “other”.

Clinical Presentation

All but one patient was diagnosed based on an initial presentation of symptoms related to or
with incidentally discovered deranged liver. Presentations ranged from acute liver failure to
incidentally elevated transaminases in a virtually asymptomatic patient. The exception was a 54-yearold man who presented primarily with neuropsychiatric symptoms, which included Parkinsonian
features, significant anxiety and intermittent depression. He had no abnormalities of liver enzymes,
however, was found to have a low serum ceruloplasmin. Diagnosis of Wilson disease was confirmed
by positive gene studies in this patient.

Laboratory values

Ceruloplasmin was available in 8 patients and ranged from 3-22U/L with a mean of 9+.7U/L.
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One patient had a normal ceruloplasmin at 22U/L, in this case the diagnosis was based on
histopathology findings and a KF ring on exam. AFP, which was also available in 8 patients, was
elevated in 4 patients (range 3 to 40U/L, mean 16+.16U/L). None of these patients however developed
Hepatocellular Carcinoma.

Eight of ten patients with available data had elevated AST levels (range 18 to 198U/L, mean
97+.62U/L) while seven of ten patients had elevated ALT levels (range 8 to 239U/L, mean
65+.67U/L). The AST/ALT levels were > 2.2 in two patients who presented with acute liver failure.
ALK levels were elevated in five patients (range 2 to 279U/L, mean 118+.80U/L). TB values were
elevated in seven of ten patients (range 0.34 to 47.8U/L, mean 10.2+.14.9U/L) while DB values were
also elevated in seven patients (range 0.06 to 39.5U/L, mean 7.3+.12.5U/L). ALK:TB ratio was less
than 4 in only 2 patients (mean ratio 11.6+5.4).

Dry Liver Copper values were available for seven patients. Six of the seven values were well
above the suggested 250mcg/g (mean 603 + 355mcg/g) cut off for Wilson’s disease. There was one
patient in the ‘Acute on Chronic Injury’ category with a liver copper value of 69 mcg/g. There was no
observed correlation between these values and the level of histopathological injury.

Urinary Copper values were available for only six patients. All values were well above the
suggested 20mcg/24h (mean 2378+ 4878mcg/24h). Values increased with increasing levels of hepatic
injury (Table 1).

Most patients presented with a coagulopathy, thrombocytopenia and anemia (mean INR
2.5+.2.4U/L, platelets of 188+.132 x103/uL and Hemoglobin (Hb) of 11+.4U/L (Table 2).
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Imaging

Right upper quadrant ultrasounds were reported on all patients. The most commonly reported
liver abnormalities were hepatomegaly, increased echogenicity, heterogeneity and nodularity consistent
with cirrhosis. The impression on imaging correlated with biopsy findings in all but one patient, in
whom there was significant steatosis but an unremarkable scan.

Histopathology

Patients were placed into three groups based on their pattern of histopathological liver injury
and clinical correlate: Near normal/mild liver injury, chronic hepatitis (which included chronic hepatitis
with or without cirrhosis), acute on chronic hepatitis and decompensated cirrhosis. Near normal was
defined as grade 0-1 fibrosis, chronic hepatitis18 as hepatocellular necroinflammatory lesions with
parenchymal dropout, lymphocytic inflammation and greater than grade 1 fibrosis, cirrhosis as defined
nodular fibrosis and acute on chronic injury was defined as lobular disarray or other acute changes on a
background of chronic hepatitis/cirrhosis.

General observations

Typical findings associated with Wilson disease were seen. These included glycogenated
nuclei, steatosis and Mallory bodies. Cases that were devoid of steatosis were cirrhotic (5 and 6) and
the most marked steatosis was seen in samples with minimal fibrosis. Hepatocyte hypereosinophila of
unclear significance was observed in two cases.
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Near normal/Mild

There were four patients in the "Near normal/mild” category. While the fibrosis grades were 01, the steatosis grades ranged from 0 – 3. Biopsies in this category were significant for mild portal
fibrosis in three of the four cases; architecture was preserved in all cases (Figure 1A). There was an
absence of interface hepatitis, lobular inflammation, Mallory hyaline, or copper accumulation by
staining. Glycogenated nuclei were seen in all cases (Figure 1B), as was patchy ballooning
degeneration. All patients were male and ranged in age from 7 -54 years. One patient presented with
non-hepatic complaints while the others were noted to have asymptomatic persistent increases in
transaminases, the most prominently elevated occurring in a patient with Stage 1 fibrosis. Bilirubin
was normal in all patients while ALK was elevated in three of the four patients. One patient, an 18
year old man, had a more marked elevation in ALT than AST, which is not typically seen in Wilson
disease. Hepatomegaly was the only ultrasonographic finding of significance in this group.
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Below are details of patients in this category

Patient #1 was a 54 y/o male who presented with predominantly neuropsychiatric complaints;
there was no steatosis in his biopsy. However glycogenated nuclei and mild ballooning degeneration
were observed.

Patient #2 was a 37y/o male evaluated for elevated transaminases. His biopsy was significant
for moderate microvesicular steatosis and glycogenated nuclei.

Patient #10 is a 7 year old male who presented with an initial diagnosis of Kawasaki's disease
(strawberry tongue, fevers). Upon further testing, abnormal liver enzymes were noted and the patient
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underwent work up for liver disease. AST, ALT were elevated at presentation, Ceruloplasmin was low
at 3. Copper and iron stains were negative. His biopsy was consistent with stage 3 steatosis, but grade
1 fibrosis. There were few glycogenated nuclei and minimal portal inflammation.

Patient #11 was an 18 year old male who presented asymptomatically with persistent elevations
in transaminases. His AST and ALT were elevated (notably, this patient had a much more elevated
ALT than AST, not typically seen in Wilson's disease). All other lab values were within normal limits.
Histopathology of the biopsy specimen revealed negative copper and iron staining, grade 3 steatosis
and grade 1 fibrosis. Abundant glycogenated nuclei were seen as well as minimal portal inflammation
and ballooning degeneration of cells.

Chronic hepatitis

There were two patients with bridging fibrosis and one with cirrhosis in this group (Figure 2A).
Sinusoidal fibrosis was also prominent in one of these cases. All three cases were devoid of significant
acute changes with mild to moderate portal inflammation, none to mild interface inflammatory activity
and only patchy ballooning degeneration and occasional acidophil bodies, (Figure 2.). Neither of the
two cases with bridging fibrosis had copper or iron deposition and steatosis was mild to focally
moderate. The cirrhotic patient had rare Mallory hyaline and copper in rare periportal hepatocytes
(Figure 2B). Steatosis was minimal in this group.

Of the patients with bridging fibrosis, one patient was male, the other female. No laboratory
data is available on either patient. The cirrhotic patient presented with features of decompensated
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cirrhosis.

Below are details of patients in this category

Patient #7 was a 35y/o female with long standing Wilson’s disease. Biopsy report showed
sinusoidal fibrosis (periportal and pericentral) with focal bridging but without cirrhosis. Lobular
disarray was noted. Fibrosis grade 3, Steatosis grade 2. Mild to moderate chronic inflammation was
noted with mild interface hepatitis and absent cholestasis or Mallory bodies. Copper and iron stain was
negative.

23
Patient #8 was a 50y/o female who was living with Wilson's since the age of 8 and on zinc
therapy; she had an orthotopic liver transplant in 2008. Her labs were notable for mild elevations in
transaminases and bilirubin as well as low platelets on presentation. Her biopsy was significant for
well established macronodular cirrhosis and mild to moderate lymphoplasmacytic infiltrates as well as
ductular proliferation. There was however no significant steatosis or glycogenated nuclei in this
patient.

Patient #12 was a 51y/o male with Wilson’s disease; there were no laboratory data available.
However, his histopathology revealed portal, periportal and bridging fibrosis, mild to moderate
lymphocytic and neutrophillic infiltrate. No glycogenated nuclei were seen. Grade 1 steatosis and few
Mallory bodies

Acute on Chronic Injury

This represented the major pattern seen in this review. There were seven patients in the “Acute
on Chronic Injury” category. There were six cases with cirrhosis and one with bridging fibrosis.
Typical markers of acute hepatic injury (i.e. parenchymal dropout, necroinflammatory activity,) were
observed in all specimens (Figure 3. A-D). More specifically, biopsies and liver explants were
significant for lobular, portal and septal inflammation of varying degrees and lobular disarray was a
consistent feature. The inflammatory infiltrate was primarily lymphocytic although eosiniphillic and
neutrophillic inflammation was seen in a minority of the specimens. Moderate to marked periportal
lymphoplasmacytic inflammation was observed in three of the specimens while mild to moderate
chronic septal lymphoplasmacytic inflammation was observed in the other four cases. Neutrophillic
inflammation was seen in only two of the seven cases. Mild to marked interface hepatitis and ductular
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activity was present in four of the seven cases. Extensive ballooning degeneration, glycogenated nuclei
and acidophil bodies were present in all of the cases while Mallory bodies and cholestasis were
observed in six of the seven specimens. Steatosis was seen in three of the seven cases, with grades of
1- 2. Copper staining was positive in five of the seven samples, staining ranged from diffusely positive
to occasional hepatocyte staining (Figure 4A, B). Iron staining was strongly positive (2+, 3+) in two
cases (Figure 4C, D)

In terms of clinical presentation, patients in this group ranged in age 13-64y/o, with a mean age
of 25. There were four females and three males. All patients presented with fulminant, subfulminant
hepatic failure or decompensated cirrhosis. Other significant clinical findings in this group included
coagulopathy and varying degrees of cytopenias. Transaminases were available for six of the seven
patients. AST levels were elevated in all but one patient. ALT levels were also elevated in six of seven
patients. AST/ALT values were greater than 2.2 in 3 of 7 patients in this category. Ceruloplasmin was
decreased in five of the six patients. TB was elevated in all patients while DB was elevated in five of
six of the patients. ALK in this group ranged from 2-163U/L, three patients presented with elevated
values. In previous studies, patients with Wilson’s disease presenting with fulminant hepatic failure
typically have ALK/TB ratios far less than 44. ALK/TB values were less than 4 in only two patients
presenting in this category (#3 and #9). There were only two patients with available dry copper values
in this category and one patient (#5) had a value below the suggested criteria for Wilson’s disease.
Interestingly, urine copper levels in this category were well above suggested criteria ranging from
1559mcg/24h to 12,265mcg/24h. Common ultrasonographic findings included shrunken
heterogeneous hyperechoic livers consistent with cirrhosis.
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Below are details of patients in this category

Patient #3 was a 14 year old female admitted in acute fulminant hepatic failure. Pathology was
notable for parenchymal loss, lymphaplasmacytic inflammation, moderate ductular proliferation and
periseptal acidophil bodies. In this case, Copper stains were variable but most prominent in periseptal
hepatocytes. In terms of other staining, iron was 1+ in macrophages and in periportal areas. The
steatosis grade was 1, with fibrosis grade 4. AST levels were elevated in this patient, ALT levels
remained normal. Chemistries were also notable for hyperbilirubinemia and anemia.

Patient #4 is a 23 year old male presenting with epigastric abdominal pain diagnosed as

27
'subfulminant hepatic failure', Liver enzymes were mildly elevated. Glycogenated nuclei were present
in his biopsy as was lymphoplasmacytic and eosinophillic portal inflammation and ballooning
degeneration. There was marked interface and ductular activity and particularly eosinophillic
hepatocytes. Copper and iron stains were negative. Fibrosis grade was 3, however there was no
steatosis.

Patient #5 was a 28 year old male with elevated transaminases and hyperbilirubinemia whose
hepatectomy specimen was noticeable for glycogenated nuclei, extensive parenchymal loss and marked
cholestasis. The copper staining on this specimen was rare. Iron stains were negative. Fibrosis grade
4, Steatosis grade zero. There were also hypereosinophillic hepatocytes in this case along with
intranodular lymphoplasmocytic inflammation. This patient had a dry copper level of 69 mcg/g
however his urine copper values were 1559mcg/g.

Patient #6 was a 19 year old female who presented from Puerto Rico with rash and abnormal
liver enzymes, further investigation revealed Wilson's. Marked portal inflammation,
lymphoplasmacytic inflammation, cholestasis and early Mallory bodies. Copper and Iron stains were
positive (with Copper being localized to periportal areas) and seen more prominently within larger
nodules. Steatosis and glycogenated nuclei was absent in this case. Patient had very mildly elevated
liver enzymes and hyperbilirubinemia.

Patient #9 was a 17 year old presented with rash and epigastric pain with abnormal liver
enzymes on presentation. This patient had a normal ceruloplasmin (22mmol/L). Her AST was
elevated but her ALT was low normal. Her alkaline phosphatase was also decreased at 2mmol/L. She
was also noted to have significant hyperbilirubinemia and mild coagulopathy. Pathology was
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significant for grade 2 steatosis, grade 4 fibrosis (cirrhosis) and positive iron and copper staining.
There were focally abundant Mallory hyaline. Mild to moderate chronic inflammation with cholestasis
and regenerative nodules were also noted.

Patient #13 was a 64 year old female with long standing Wilson’s disease. She had been treated
with penicillamine and was switched to zinc because of poor tolerance of the former. The patient
eventually had an OLT in 2007 due to acute liver failure. AST and ALT were elevated (AST/ALT>2).
Notably in this patient’s labs were an increased total bilirubin with normal direct (perhaps due to
hemolytic anemia seen in Wilson's patients). Histopathology revealed grade 2 steatosis and grade 4
fibrosis with iron and copper stains both being positive in occasional hepatocytes. There was mild
septal inflammation, marked cholestasis, glycogenated nuclei and some Mallory bodies.

Patient #14 is a 13y/o male received as a consult whose biopsy was negative for both iron and
copper. Significant findings in the specimen included mild steatosis and grade 3 bridging fibrosis.
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Discussion

As demonstrated in this review, both the anatomic and clinical presentations of Wilson’s
disease are heterogeneous. Its course is also affected by timing and tolerance of treatment. As
demonstrated in prior studies, the earlier the treatment, the better the outcome. In this study, we aimed
to first categorize these patients on the basis of histopathological injury of their biopsies and
hepatectomies. The pathology and clinical parameters were then detailed and attempts were made at
correlation.

Our review supports the pathology of the early stages of Wilson disease as represented by
steatosis and glycogenated nuclei, often without accumulation of copper. The most consistent finding
in this group of near normal liver biopsies is glycogenated nuclei. The pathogenesis of these
glycogenated nuclei is largely unknown, however, it has been described to be due to complex sugars
that deposit in the nuclei of the hepatocyte. Glycogenated nuclei have been seen in NASH (NonAlcoholic Steatohepatitis), Diabetes Mellitus and Wilson’s disease years before symptoms begin14. It
is however presumed that this fairly nonspecific finding may represent very early hepatic injury even
though glycogenated nuclei have been observed in biopsies of healthy individuals14.

Interestingly, with worsening of histopathological injury from near normal to definite chronic
hepatitis to acute on chronic injury, the findings found in this review were not entirely consistent with
those detailed before14. This provides further evidence of the difficulty of the diagnosis of Wilson’s
disease for the pathologist. In the ‘Chronic Hepatitis NOS’ category, for example, lymphoplasmacytic
inflammation has been suggested as a feature to distinguish Wilson’s disease hepatitis from hepatitides
of other etiologies14 but is clearly not a specific enough change to utilize in this setting. It is important
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to note however that the previously ubiquitous glycogenated nuclei found in early stages of the disease
were notably absent in cases of chronic hepatitis and compensated cirrhosis. In addition unlike
previous reports, copper staining was rare if not absent in most of these cases.

Oddly, as the disease appears to progress, either as decompensated cirrhosis or acute injury on
chronic hepatitis, abundant glycogenated nuclei are seen. Of note, in this category, there was also one
case with giant cell change, a finding typically seen in autoimmune hepatitis. This patient however did
not fulfill diagnostic criteria of autoimmune hepatitis.

Another significant observation is the overlap between acute on chronic liver injury in Wilson’s
disease and other features such as cholestasis and iron overload. In particular, since ultrastructural
features may overlap with those of other cholestatic disorders, ultrastractural analysis may have limited
application in patients with acute liver injury and cholestasis.

Diagnosis: Anatomic and Clinical pathology correlations

Early diagnosis of Wilson's disease is necessary, as treatment with copper chelators has been
proven to delay the subsequent hepatic and lenticular degeneration cause by copper buildup. Thus
thorough characterization of patients presenting in this review's “Near Normal/Mild” category is
essential. As seen above, cases in this category were significant for mild elevations in transaminases
on clinical presentation and steatosis and glycogenated nuclei on biopsy. Presented as such, this
perhaps generates the largest differential for the pathologist without any further molecular or genetic
studies given that in all four cases iron and copper staining were negative. The differential may include
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any of the far more common causes of mild chronic hepatitis (autoimmune, viral, toxin). Regarding
trends of clinical parameters in this group, there were varying elevations in transaminases (mostly
AST>ALT as seen in previous reports of Wilson's disease). Importantly, transaminases were not as
high as the levels seen in the viral hepatitides (AST and ALT levels are often 5 – 10 times the upper
level of normal) nor were AST/ALT ratios greater than two as typically seen in alcoholic hepatitis.
Dry copper levels were also elevated. However, Total and Direct Bilirubin were normal in all cases but
one. Here, as mentioned in previous studies, copper quantization proves to be the only definite clinical
lab value in diagnosing liver disease. It is therefore imperative that when this minimal degree of liver
changes are noted, if a suspicion exists for Wilson disease based on other parameters, liver quantization
is performed.

In the subsequent groups representing patients with increasing hepatic injury due to Wilson’s
disease, clinical parameters (transaminases) increased with hepatic injury but were not consistent with
previous reports. AST/ALT ratios in the acute on chronic category were greater than 2.2 in only two
patients, the same number had ALK/TB ratios less than 4. This is unlike previous studies which have
shown that the combination of AST/ALT > 2.2 and ALK/TB > 4 is consistent with Wilson’s disease in
patients presenting with acute liver failure. This is a retrospective study and it is important to note that
some of the patients at Yale New Haven Hospital were already on treatment at the time of their
presentation, this may have skewed the results. Also, such differences in transaminase and bilirubin
levels illustrate the unreliability of solely clinical parameters in diagnosing Wilson’s disease.

While dry copper levels did not increase with increasing levels of hepatic injury, urine copper
levels – in those patients with available data – did. This finding may prove important in diagnosing
and following patients with Wilson’s disease. Dry copper levels have been the gold standard of
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diagnosis but this study shows a patient with Wilson’s disease with a dry copper level of 69mcg/g, well
under the suggested criteria of 250mcg/g. His urine however surpassed the cut-off and diagnosis was
confirmed. Apart from illustrating the difficulty of diagnosis, this finding shows urine copper to
perhaps be more reliable in assessing not only the presence but the severity of Wilson’s disease. There
are however difficulties with collection of 24h urine samples and many opportunities for
contamination.

This study replicates the often-repeated observation that a negative liver copper stain does not
exclude Wilson disease. Previous investigation into Timm's silver stain (not used in this study) found
it to be sensitive to the cytosolic distribution of copper in the early stages of Wilson's disease. The
standard rhodanine and rubeanic stains are often negative at these stages19. In a study to assess the
sensitivity of the three most commonly used stains (Timm's, rhodanine and orcein), 79 liver biopsies
from patients with Wilson's disease were categorized into three different groups: steatosis, interface
hepatitis and chronic hepatitis/cirrhosis. Timm's s silver stain was found to be more sensitive in its
detection of copper in all three groups. This study also demonstrated the unreliability of histochemical
detection of copper in Wilson's disease. Timm's silver stain, for example, only stained 58.6% of
biopsies with chronic hepatitis/cirrhosis, 40.1% of biopsies with interface hepatitis and 30.4% with
steatosis. It has been suggested that Timm's be used in referred cases with limited tissue available for
staining19.

In addition to emphasizing the fallibility of the copper stain, this study shows the absence of
any correlation between copper staining and dry copper levels. In fact, positive copper and iron stains
seemed to correlate more with increasing tissue injury than actual copper levels. Patient #5 – in the
acute on chronic injury category - for example had a dry copper level of 69mcg/g and a positive copper
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stain, while Patient #1 – in the near normal/mild category – had a dry copper level of 650mcg/g with a
negative copper stain. This difference may be because rhodanine is less likely to stain the abundant
cytoplasmic copper present in early stages of the disease and may be more apt to stain lysosomal
copper present in advanced stages of the disease.

Interestingly also, only a minority of patients have bland chronic hepatitis, with or without
cirrhosis. The vast majority of cases reported here show some degree of acute liver injury, exemplified
by any combination of ballooning degeneration, apoptosis, parenchymal dropout with lobular collapse.
In addition, as has been observed, in these cases with acute injury, cholestasis is a prominent feature, as
is some measure of disordered iron metabolism and increased iron.

The iron overload noted in the specimens in the acute on chronic liver injury category can be
due to the intravascular hemolysis seen in some reported cases of Wilson’s disease, unfortunately there
were no serum iron levels to correlate with the histopathological findings. The suggested cause of this
hemolytic anemia is the increased oxidative stress caused by copper accumulation within the cells20.

The iron overload could also be due to the hypoceruloplasminemia (and potentially, the
hypocupremia) in these patients. As mentioned before though not completely characterized,
ceruloplasmin is a ferroxidase essential for iron mobilization and transport thus it can be assumed that
the decreased ceruloplasmin seen in Wilson’s disease patients would lead to a build up of iron in major
organs of the body and an absence thereof in the serum. Aceruloplasminemia, an autosomal recessive
disease caused by loss of function mutations in the ceruloplasmin gene, illustrates the effect of low to
absent ceruloplasmin on iron metabolism. In this case, iron mobilization is severely impaired and
builds up in the pancreas, liver and brain. Hypoceruloplasminemia does not wholly explain iron
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overload however as iron staining was positive in one of the reviewed cases, this patient had a
ceruloplasmin of 22U/L. It is important to note though that ceruloplasmin is an acute phase reactant,
thus high levels are to be expected in patients with acute on chronic injury.

Nevertheless, iron proves to be an important marker of liver injury in the context of Wilson's
disease as copper has been previously found to play a crucial role in its metabolism not only in the
context of ceruloplasmin but also in Cu dependent ATPases. The ATP7A/ATP7B homologue found in
Saccharomyces cervisae yeast Ccc2p has been characterized in previous studies as a copper dependent
ATPase necessary for iron uptake21. In future studies, in addition to the clinical parameters detailed
above, it may be worthwhile to correlate dry iron levels with disease states in order to further detail
diagnostic criteria, and to determine whether liver iron levels may be a useful marker of acute liver
injury in the setting of Wilson disease.

Because of the relative recent incorporation of molecular diagnostics into clinical practice and
the rare nature of Wilson's disease, it is important to note that although Wilson's disease is
characterized by a mutation in ATP7B, other mutations in other copper dependent ATPases or copper
dependent proteins may be implicated in this disease of copper accumulation. These varying mutations
may potentially account for both the varied clinical presentations and varied patterns of
histopathological injury seen above.

Previous reports4 have categorized the clinical and pathological features in patients with Wilson
disease into: fatty liver, acute hepatitis, resembling autoimmune hepatitis, cirrhosis: compensated or
decompensated and acute liver failure. In this series, none of these patients with acute liver failure was
without cirrhosis thus it may be possible that in some settings, such acute liver failure occurs only in
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the present of extensive prolonged liver damage.

In this review, a clinical presentation of acute liver injury correlates with the histological
features though not entirely consistent with previous reports. Correlation between other histological
features and clinical parameters is less clear, though some trends were noted. As seen in this study,
despite varying levels, the ceruloplasmin remained low, if not low normal in most cases. Though
copper staining has proved an unreliable method for initial diagnosis, the most severe cases with acute
injury were more likely to stain positively with copper and therefore, unlike ceruloplasmin, may
possibly correlate with severity of acute injury. In addition, and perhaps most important, urine copper
appears to correlate closely with hepatic injury and was positive in a case of Wilson’s disease in which
dry liver copper was negative (according to diagnostic criteria). Thus, this may prove beneficial in
diagnosing and trending of disease although further studies are warranted. Testing urinary copper also
employs a far less invasive (and presumably safer) method of testing. Both patient and physician
should be thoroughly educated on 24h urine collection (avoidance of tap water and Foley catheters,
usage of pediatric urine bags that do not contain copper) so as to minimize contamination.

The characterization of Wilson disease still remains a challenge and while advances in
molecular techniques may theoretically be able to facilitate diagnosis, these may prove prohibitively
expensive given the increasing number of ATP7B mutations and the lack of prevalence of the disease.
A thorough awareness of clinical presentation, varying histopathological features and clinical
parameters that provide hints to both disease process and severity is therefore be useful in the clinical
management and diagnosis of Wilson’s disease.
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